Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

Diabetes Care

Volumn 28, Issue 10, 2005, Pages 2345-2351

  Eurich, Dean T ^a,b   Majumdar, Sumit R ^a,b   McAlister, Finlay A ^a,b   Tsuyuki, Ross T ^a,b   Johnson, Jeffrey A ^a,b,c  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RISK BENEFIT ANALYSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MORBIDITY; SASKATCHEWAN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 25644459350     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.10.2345     Document Type: Article

References (39)

1. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, Bauters C: Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25:656-662, 2004
2. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44:1587-1592, 2004
3. Majumdar SR, McAlister FA, Cree M, Chang WC, Packer M, Armstrong PW: Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Clin Ther 26:694-703, 2004
4. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin Alc with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141:413-420, 2004
5. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431, 2004
6. American Society of Health-System Pharmacists: AHFS Drug Information. Bethesda, MD, American Society of Health-System Pharmacists, 2004
7. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29-34, 1974
8. Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:1614-1619, 2001
9. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81-85, 2003
10. Holstein A, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin therapy are largely disregarded. Diabet Med 16:692-696, 1999
11. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R: Frequency of inappropriate metformin prescriptions. JAMA 287:2504-2505, 2002
12. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: The Multicenter Metformin Study Group. N Engl J Med 333:541-549, 1995
13. Grant PJ: The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19:64-66, 1996
14. Wulffele MG, Kooy A, Zeeuw D, Stehouwer CDA, Gansevoort RT: The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1-14, 2004
15. U.K. Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
16. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellitus. Diabetes Care 25:2244-2248, 2002
17. Misbin RI: The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27:1791-1793, 2004
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: 2002. In The Cochrane Library [serial online]. Issue 2. Oxford, U. K., Updated software, 2002
19. Lalau JD, Race JM: Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 20:377-384, 1999
20. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB: Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 255:179-187, 2004
21. Marciniak TA, Ellerbeck EF, Radford MJ, Kresowik TF, Gold JA, Krumholz HM, Kiefe CI, Allman RM, Vogel RA, Jencks SF: Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 279:1351-1357, 1998
22. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590, 2005
23. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA: Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 27: 1330-1334, 2004
24. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506, 1992
25. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332-336, 2000
26. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr: Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:699-703, 2004
27. Goff DC Jr, Pandey DK, Chan FA, Ortiz C, Nichaman MZ: Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 160:197-202, 2000
28. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care 33:783-795, 1995
29. Johnson RE, Hornbrook MC, Nichols GA: Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol 47:1191-1199, 1994
30. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203, 1992
31. Schneeweiss S, Maclure M: Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 29:891-898, 2000
32. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
33. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
34. Leibowitz G, Cerasi E: Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 39:503-514, 1996
35. Meinert CL, Knatterud GL, Prout TE, Klimt CR: The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl. 2): 787-830, 1970
36. Laupacis A, Mamdani M: Observational studies of treatment effectiveness: some cautions. Ann Intern Med 140:923-924, 2004
37. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
38. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
39. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW: Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004-1009, 2004